Comprehensive Analysis of Transcriptomic Biomarkers for Predicting Response to Atezolizumab Plus Bevacizumab Immunotherapy in Hepatocellular Carcinoma

Affiliations

• ¹ Division of Hepatobiliary and Transplantation Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, China.
• ² Department of Hepatobiliary Surgery, Innovative Institute of Tumor Immunity and Medicine (ITIM), Anhui Province Key Laboratory of Tumor Immune Microenvironment and Immunotherapy, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.